雄激素受体基因CAG短串联重复序列与肿瘤发生和预后的关联研究进展

谢佳新; 沈舒宁

doi:10.16462/j.cnki.zhjbkz.2020.03.021

雄激素受体基因CAG短串联重复序列与肿瘤发生和预后的关联研究进展

doi: 10.16462/j.cnki.zhjbkz.2020.03.021

谢佳新^1, ,,
沈舒宁²

1.
400038 重庆, 陆军军医大学高原军事医学系高原作业医学教研室, 极端环境医学教育部重点实验室, 全军高原医学重点实验室
2.
100094 北京, 解放军第984医院

基金项目: 国家自然科学基金(81803294);河北省自然科学基金(H2015509001)

详细信息

通讯作者:
谢佳新, E-mail:xiejiaxin1006@163.com

中图分类号: R373.21;R512.6;R181
计量
- 文章访问数: 403
- HTML全文浏览量: 135
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-10
- 修回日期: 2019-09-17
- 刊出日期: 2020-03-10

Review on the association of CAG short tandem repeats of androgen receptor gene with tumorigenesis and prognosis

XIE Jia-xin^{1
, ,},
SHEN Shu-ning²

1.
Department of High Altitude Operation Medicine, College of High Altitude Military Medicine, Army Medical University, Key Laboratory of Extreme Environmental Medicine, Ministry of Education of China, Key Laboratory of High Altitude Medicine, PLA, Chongqing 400038, China
2.
The 984th Hospital of PLA, Beijing 100094, China

Funds: National Natural Science Foundation of China(81803294); Natural Science Foundation of Hebei Province(H2015509001)

More Information

Corresponding author: XIE Jia-xin, E-mail:xiejiaxin1006@163.com

摘要

摘要: 雄激素受体(androgen receptor, AR)及其介导的信号通路异常与人类多种疾病的发生、转归及预后密切相关, 并在一定程度上导致疾病的性别差异, 其具体机制尚不明确。AR基因第1外显子CAG短串联重复序列(short tandem repeat, STR)与AR转录调节活性存在负相关性, 影响靶蛋白合成与生物学功能, 在前列腺癌、乳腺癌、膀胱癌、肝癌、子宫内膜癌等多种肿瘤发生发展及预后中扮演重要角色。本文对目前AR基因CAG STR与常见肿瘤相关性研究进行综述, 为进一步探索AR导致相关肿瘤高发和性别差异作用机制和筛选肿瘤高危人群提供线索。
- 雄激素受体 /
- 肿瘤 /
- 短串联重复序列 /
- 多态性
Abstract: Abnormal expression of androgen receptor(AR) and AR-mediated signaling pathways are closely related to the occurrence, outcome, and prognosis of various human disease, and to some extent, AR lead to gender differences in these diseases. However, the specific mechanism is still unclear. CAG short tandem repeat(STR) sequence in exon 1 of AR gene negatively correlates with the transcriptional regulation activity, affects the synthesis and biological function of the target proteins, and plays an important role in the development and prognosis of various tumors, such as prostate cancer, breast cancer, bladder cancer, liver cancer, and endometrial cancer. In this review, we summarized the current studies on the association between AR gene CAG STR and the common tumors, in order to provide clues for further exploring the mechanism of AR-related tumors with high incidence and gender differences, and screening populations with high risk for the corresponding tumors.
- Androgen receptor /
- Tumor /
- Short tandem repeat /
- Polymorphism

HTML全文

图 1 雄激素受体信号通路示意图

Figure 1. The schematic map of androgen receptor signaling pathway

下载: 全尺寸图片幻灯片

表 1 AR基因CAG重复序列多态性在常见肿瘤发生发展中的作用

Table 1. The role of CAG repeat polymorphism of AR gene in the occurrence and development of common tumors

肿瘤	作用因子或信号通路	作用特点
前列腺癌	EGF、TGF-β、IGF1、Wnt/β-Catenin、miR-4496、miRNA-200a	汉族人群中短(CAG)n增加发病风险, 且恶性程度高, 国外人群中相关性尚不确定
乳腺癌	ER、PR、HER-2、E-cadherin、Cyclin D1、p21、p27	长(CAG)n增加发病风险, 提示不良预后
膀胱癌	CD24、UGT1A、Wnt/β-catenin、c-myc、p53、TGF-β、E-cadherin、EGFR、ERBB2	短(CAG)n增加发病风险;
肝癌	HBx、TGF-β1、VEGF、CCRK、miR-216a、p38、NF-ΚB/MMP9	短(CAG)n增加男性发病风险, 预后差; 长(CAG)n在HBV阳性, 尤其是具有肝癌家族史女性中常见
子宫内膜癌	IGF-1R、Cyclin D1、PI3K/MAPK、CD133	国外女性中长(CAG)n增加发病风险, 汉族女性未见报道

下载: 导出CSV

参考文献(35)

[1]	Dong H, Xu J, Li W, et al. Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis[J]. J Pathol, 2017, 241(4): 448-462. DOI: 10.1002/path.4839.
[2]	赵玲, 魏兆莲.雄激素受体在多囊卵巢综合征卵巢中表达的研究[J].中华疾病控制杂志, 2011, 15(8): 660-662. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jbkzzz201108006 Zhao L, Wei ZL. Study of androgen receptor expression in ovary of polycystic ovary syndrome[J]. Chin J Dis Control Prev, 2011, 15(8): 660-662. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jbkzzz201108006
[3]	Ao J, Meng J, Zhu L, et al. Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion[J]. Mol Oncol, 2012, 6(5): 507-515. DOI: 10.1016/j.molonc.2012.06.005.
[4]	Nadal M, Prekovic S, Gallastegui N, et al. Structure of the homodimeric androgen receptor ligand-binding domain[J]. Nat Commun, 2017, 8: 14388. DOI: 10.1038/ncomms14388.
[5]	Wu JT, Hu JH, Liu QZ, et al. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition[J]. Andrologia, 2014, 46(10): 1128-1133. DOI: 10.1111/and.12203.
[6]	Wang SH, Yeh SH, Shiau CW, et al. Sorafenib action in hepatitis B virus X-activated oncogenic androgen pathway in liver through SHP-1[J]. J Natl Cancer Inst, 2015, 107(10): djv190. DOI: 10.1093/jnci/djv190.
[7]	Chan QK, Lam HM, Ng CF, et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2)cell-cycle arrest[J]. Cell Death Differ, 2010, 17(9): 1511-1523. DOI: 10.1038/cdd.2010.20.
[8]	Ashikari D, Takayama K, Tanaka T, et al. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer[J]. Oncogene, 2017, 36(45): 6272-6281. DOI: 10.1038/onc.2017.225.
[9]	Zubair H, Bhardwaj A, Ahmad A, et al. Hydroxytyrosol induces apoptosis and cell cycle arrest and suppresses multiple oncogenic signaling pathways in prostate cancer cells[J]. Nutr Cancer, 2017, 69(6): 932-942. DOI: 10.1080/01635581.2017.1339818.
[10]	Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators(SARMs)[J]. Mol Cell Endocrinol, 2018, 465: 134-142. DOI: 10.1016/j.mce.2017.06.013.
[11]	Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene[J]. Asian J Androl, 2007, 9(2): 147-179. DOI: 10.1111/j.1745-7262.2007.00250.x.
[12]	Panet-Raymond V, Gottlieb B, Beitel LK, et al. Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor[J]. Neurotox Res, 2001, 3(3): 259-275. doi: 10.1007/BF03033265
[13]	Mobasseri N, Babaei F, Karimian M, et al. Androgen receptor(AR)-CAG trinucleotide repeat length and idiopathic male infertility: a case-control trial and a Meta-analysis[J]. EXCLI J, 2018, 17: 1167-1179. DOI: 10.17179/excli2018-1744.
[14]	梁国庆, 顾燕青, 沈薇, 等.雄激素受体基因CAG多态性对前列腺癌恶性程度的影响[J].现代泌尿外科杂志, 2015, 20(6): 420-422. DOI: 10.3969/j.issn.1009-8291.2015.06.016. Liang GQ, Gu YQ, Shen W, et al. Effect of androgen receptor gene(CAG)n polymorphism repeats on the severity of prostate cancer[J]. J Mod Urol, 2015, 20(6): 420-422. DOI: 10.3969/j.issn.1009-8291.2015.06.016.
[15]	Soni A, Bansal A, Mishra AK, et al. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population[J]. Genet Test Mol Biomarkers, 2012, 16(8): 835-840. DOI: 10.1089/gtmb.2011.0322.
[16]	Gómez R, Torres-Sánchez L, Camacho-Mejorado R, et al. Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men[J]. J Hum Genet, 2016, 61(9): 781-786. DOI: 10.1038/jhg.2016.49.
[17]	Kachakova D, Mitkova A, Popov E, et al. Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2 and prostate cancer risk and aggressiveness in Bulgarian patients[J]. Turk J Med Sci, 2016, 46(3): 626-640. DOI: 10.3906/sag-1501-124.
[18]	Qin Z, Li X, Han P, et al. Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and Meta-analysis[J]. Medicine(Baltimore), 2017, 96(25): e7258. DOI: 10.1097/MD.0000000000007258.
[19]	王晓明, 孙亮, 张政, 等.雄激素受体CAG重复多态性与BPH和PCa相关性的Meta分析[J].中华男科学杂志, 2014, 20(2): 172-176. DOI: 10.13263/j.cnki.Nja.2014.02.016. Wang XM, Sun L, Zhang Z, et al. Correlation of androgen receptor CAG repeats with the risks of benign prostatic hyperplasia and prostate cancer: A Meta-analysis[J]. Nat J Androl, 2014, 20(2): 172-176. DOI: 10.13263/j.cnki.Nja.2014.02.016.
[20]	Dang J, Peng L, Zhong HJ, et al. Androgen receptor(CAG)n polymorphisms and breast cancer risk in a Han Chinese population[J]. Genet Mol Res, 2015, 14(3): 10258-10266. DOI: 10.4238/2015.August.28.10.
[21]	梦洁, 付丽. AR基因外显子1的CAG重复多态性与乳腺癌发生的关系[J].实用癌症杂志, 2012, 27(1): 24-26. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=syazzz201201008 Meng J, Fu L. Androgen receptor gene polymorphism and breast cancer risk[J]. The Practical Journal of Cancer, 2012, 27(1): 24-26. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=syazzz201201008
[22]	Lee YT, Liu HM, Lee LH, et al. The polymorphism of CAG repeats in the androgen receptor gene and breast cancer mortality[J]. Cancer Biomark, 2015, 15(6): 815-822. DOI: 10.3233/CBM-150525.
[23]	Cogliati P, Ciniselli CM, Agresti R, et al. Androgen receptor CAG repeat length and estrogen receptor status in postmenopausal breast cancer prognosis[J]. Int J Biol Markers, 2015, 30(4): 418-424. DOI: 10.5301/jbm.5000176.
[24]	Mao Q, Qiu M, Dong G, et al. CAG repeat polymorphisms in the androgen receptor and breast cancer risk in women: a Meta-analysis of 17 studies[J]. Onco Targets Ther, 2015, 8: 2111-2120. DOI: 10.2147/OTT.S85130.
[25]	Mizushima T, Tirador KA, Miyamoto H. Androgen receptor activation: a prospective therapeutic target for bladder cancer?[J]Expert Opin Ther Targets, 2017, 21(3): 249-257. DOI: 10.1080/14728222.2017.1280468.
[26]	Teng XY, Liu GQ, Diao XL, et al. CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma[J]. Oncol Rep, 2010, 23(3): 811-818.
[27]	Tian Y, Kuo CF, Chen WL, et al. Enhancement of hepatitis B virus replication by androgen and its receptor in mice[J]. J Virol, 2012, 86(4): 1904-1910. doi: 10.1128/JVI.06707-11
[28]	Liu B, Wen X, Huang C, et al. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years[J]. Int J Biochem Cell Biol, 2013, 45(9): 1987-1996. DOI: 10.1016/j.biocel.2013.06.017.
[29]	Yeh SH, Chiu CM, Chen CL, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma[J]. Int J Cancer, 2007, 120(8): 1610-1617. DOI: 10.1002/ijc.22479.
[30]	Li K, Zhong C, Wang J, et al. Association of androgen receptor exon 1 CAG repeat length with risk of hepatocellular carcinoma: a case-control study[J]. Tumour Biol, 2014, 35(12): 12519-12523. DOI: 10.1007/s13277-014-2570-0.
[31]	Yu MW, Cheng SW, Lin MW, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma[J]. J Natl Cancer Inst, 2000, 92(24): 2023-2028. DOI: 10.1093/jnci/92.24.2023.
[32]	Yu MW, Yang YC, Yang SY, et al. Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women[J]. Hepatology, 2002, 36(1): 156-163. DOI: 10.1053/jhep.2002.33897.
[33]	Zadeh SL, Duska LR, Mills AM. Androgen receptor expression in endometrial carcinoma[J]. Int J Gynecol Pathol, 2018, 7(2): 167-173. DOI: 10.1097/PGP.0000000000000401.
[34]	Tangen IL, Onyango TB, Kopperud R, et al. Androgen receptor as potential therapeutic target in metastatic endometrial cancer[J]. Oncotarget, 2016, 7(31): 49289-49298. DOI: 10.18632/oncotarget.10334.
[35]	Ashton KA, Proietto A, Otton G, et al. Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk[J]. Cancer Epidemiol, 2010, 34(3): 328-337. DOI: 10.1016/j.canep.2010.03.005.